Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 20.43 USD 4.72% Market Closed
Market Cap: 1.3B USD

Operating Margin
Uniqure NV

-1 142.1%
Current
-722%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 142.1%
=
Operating Profit
-179.9m
/
Revenue
15.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NL
Uniqure NV
NASDAQ:QURE
1.3B USD
-1 142%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
402B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.8B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
28%
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD
8%
No Stocks Found

Uniqure NV
Glance View

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
27.5 USD
Undervaluation 26%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 142.1%
=
Operating Profit
-179.9m
/
Revenue
15.8m
What is the Operating Margin of Uniqure NV?

Based on Uniqure NV's most recent financial statements, the company has Operating Margin of -1 142.1%.

Back to Top